This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
10 Top-Ranked ETFs That Have Outperformed in 2020
by Sweta Killa
The coronavirus outbreak notwithstanding, 2020 has been shaping up as a blockbuster year.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Top Two Sector ETFs of Past Decade Still on High Momentum
by Sanghamitra Saha
These ETFs have emerged as one of the top performers in the past decade.
10 Top-Performing ETFs of the Past Decade
by Sanghamitra Saha
These ETFs have emerged as one of the top performers in the past decade.
Biotech ETF (XBI) Hits New 52-Week High
by Sanghamitra Saha
The biotech ETF hits a 52-week high on Nov 27. Can it soar further?
ETF Sectors to Bet on Positive Vaccine News
by Sweta Jaiswal, FRM
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
ETFs to Bet on Biden's Potential Presidential Victory
by Sweta Killa
Though the election results are yet to become official, many sectors are expected to benefit on Biden's potential victory.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Here's Why Healthcare ETFs Are Rallying Post Elections
by Sweta Jaiswal, FRM
Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.